An international panel of nuclear medicine experts gathered for the Biograph Vision Quadra™1 Meet and Greet earlier this year. Hosted by Siemens Healthineers, this three-hour virtual meeting gathered representatives from leading clinical and research facilities to hear first-hand how teams from across five countries are using the latest member of the Biograph™ PET/CT family for clinical and research advancement and to exchange insight on the future of simultaneous whole-body PET/CT.
Generously giving their time, the scientists, physicians, and technicians formed this diverse group of individuals all working with Biograph Vision Quadra to push the boundaries of medicine further with PET/CT scanners that feature large PET axial field of view (aFOV). Many key takeaways resulted from the experts sharing their observations, including discovering that Biograph Vision Quadra is used just as much for clinical applications as it is research, demonstrating the versatility of the scanner’s unique dimensions. Trends were also identified, like leveraging the larger PET FOV and how high-sensitivity users can reduce dose and acquisition time while maximizing image quality.
Founded on Biograph Vision™ technology that has demonstrated increased detectability and outstanding image detail and definition, Biograph Vision Quadra is no exception. The scanner’s excellent image quality and superb small lesion visualization was observed, demonstrating the value of 106-cm PET aFOV for low dose, fast scanning, dynamic visualization of motion, and a variety of radiopharmaceuticals, including exceptional low-energy radioisotope images.
Biograph Vision Quadra
Data and images courtesy of Inselspital, Bern University Hospital, Switzerland.
Users shared their experiences and future plans
Aha moments and lessons learned were interspersed throughout the collaborative session, as well as the ever-useful tips and tricks. Users shared experiences, challenges, and solutions covering department workflow, protocol design, reconstruction techniques, the impact of COVID, and big data management, while also discussing ideas for future improvement in these areas.
Looking ahead, these healthcare professionals expressed plans and interest in new radiopharmaceutical development, expanding the capabilities of dynamic imaging with different protocol designs, dosimetry, and advancing motion correction techniques with deep inspiration breath-hold and artificial intelligence (AI). Additionally, they discussed how AI-based image optimization can play a part in big data management. Developing ultra-low dose protocols and alternate attenuation correction techniques sparked conversation in relation to PET/CT utilization for screening and trials.
“Today, clinical research in molecular imaging is translating into practice and benefits for patients at an accelerating pace. We greatly appreciate hearing from six innovative healthcare institutions on how they are making these advancements a reality with Biograph Vision Quadra,” remarks James Williams, PhD, head of the Molecular Imaging Business Line at Siemens Healthineers. During the current challenging climate, Siemens Healthineers greatly appreciated the opportunity to virtually gather a diverse group of current and future Biograph Vision Quadra users and hear firsthand how the system is being utilized, while also providing a moment to interact with developers and innovators to share plans for the future of Biograph Vision Quadra.